

PRIOR AUTHORIZATION REQUEST FORM
CLOSTRIDIUM DIFFICILE DRUGS

Dificid[®], Zinplava[™]

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Dificid[®] (fidaxomicin), Zinplava[™] (bezlotuxumab)

Dosing/Frequency: _____

Questions	Yes	No	Comments/Notes
1. Does the member have a diagnosis of C. diff based on diarrheal symptoms AND positive stool toxin test or PCR?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
INITIAL EPISODE ADULT			
1. Is this an initial episode of C. diff in an adult?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does documentation show a trial and failure of at least 10 days of oral vancomycin?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
INITIAL EPISODE PEDIATRIC			
1. Is this an initial episode of C. diff in a pediatric member (<18 years old)?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does documentation show a trial and failure of oral vancomycin or metronidazole?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
RECURRENT C. diff INFECTION			
1. Is the request for recurrent C. diff infection?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Does documentation show at least one of the following: <ul style="list-style-type: none"> • A pulsed or tapered vancomycin regimen OR a second 10-day course has been trialed and failed • If metronidazole was used for primary episode, a standard 10-day course of vancomycin has been tried and failed 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
ZINPLAVA[™]			
1. Is the request for prophylaxis therapy with Zinplava [™] ?	<input type="checkbox"/>	<input type="checkbox"/>	

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

2. Has the member had at least 2 confirmed recurrent C. Diff episodes (3 total)?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Does documentation show that the second recurrence was treated with pulsed or tapered vancomycin?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Will the member concurrently receive vancomycin or metronidazole?	<input type="checkbox"/>	<input type="checkbox"/>	
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM-015
 Origination Date: 02/14/2018
 Reviewed/Revised Date: 03/25/2020
 Next Review Date: 03/25/2021
 Current Effective Date: 03/26/2020

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.